Market Research Logo

Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)

Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)

Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin. A person inherits four genes to produce alpha globin protein and two genes to produce alpha globin protein from parents. Thalassemia is caused by any abnormality or mutation in one or more genes responsible for hemoglobin production. When a person inherits only one affected gene from parents then the person becomes a carrier of thalassemia. Since, thalassemia is an inherited disorder; one of the parents must be a carrier for thalassemia. When both the parents are carriers then the risk of giving birth to a thalassemia affected child is quite high. Thalassemia is generally of two types: alpha thalassemia and beta thalassemia.

Globally, thalassemia affects approximately 7% of the population and many of them are transfusion dependent patients. The global thalassemia market is likely to be driven with the growing market of bone marrow transplant and blood transfusion therapy, supported by high numbers of transfusion dependent patients.

The U.S. is expected to be the first region to start selling of thalassemia drugs due to developing drug pipeline and later on, market penetration of thalassemia drugs would occur in Europe. U.S. and Europe have high prevalence of severe forms of beta-thalassemia which would result into a high demand for thalassemia drugs in future.

The global thalassemia market is expected to grow in future with mounting prevalence of thalassemia, rising Asian population, increasing healthcare expenditure, rising spending on pharmaceuticals R&D and stem cell therapy research. Key trends of this market include progressing drug pipeline, rising scope for gene therapy and growing awareness towards thalassemia. However, there are some factors which can hinder growth of the market including regulatory changes, associated risks and high cost of treatment.

The report “Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering U.S, and Europe along with the global market. The report profiles key players of the market including GlaxoSmithKline Plc, Celgene, Bluebird Bio and Bellicum Pharmaceuticals.


1. Introduction
1.1 Thalassemia
1.2 Types of Thalassemia
Table 1: Types of Thalassemia
1.3 Diagnosis and Treatment
2. Global Thalassemia Market
2.1 Thalassemia Population by Category
Table 2: Global Thalassemia Population by Category (2016)
2.2 Thalassemia Market by Treatment
2.2.1 Global Bone Marrow Market Forecast by Value
Table 3: Global Bone Marrow Market Forecast by Value (2016-2021)
2.2.2 Global Luspatercept Revenue Forecast for Beta-Thalassemia
Table 4: Global Luspatercept Revenue Forecast for Beta-Thalassemia (2019-2025)
3. Regional Market Analysis
3.1 The U.S.
3.1.1 The U.S. Beta-Thalassemia Patient Volume Forecast
Table 5: The U.S. Beta-Thalassemia Patient Volume Forecast (2016-2021)
3.1.2 The U.S. Beta-Thalassemia Intermedia/Major Patient Volume Forecast
Table 6: The U.S. Beta-Thalassemia Intermedia/Major Patient Volume Forecast (2016-2021)
3.1.3 The U.S. Beta-Thalassemia Intermedia/Major Patient Volume by Category
Table 7: The U.S. Beta-Thalassemia Intermedia/Major Patient Volume by Category (2016)
3.1.4 The U.S. Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast
Table 8: The U.S. Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast (2016-2021)
3.1.5 The U.S. Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast
Table 9: The U.S. Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast (2016-2021)
3.1.6 The U.S. Luspatercept Drug Revenue Forecast for Beta-Thalassemia
Table 10: The U.S. Luspatercept Drug Revenue Forecast for Beta-Thalassemia (2019-2025)
3.2 Europe
3.2.1 Europe Beta-Thalassemia Patient Volume Forecast
Table 11: Europe Beta-Thalassemia Patient Volume Forecast (2016-2021)
3.2.2 Europe Beta-Thalassemia Intermedia/Major Patient Volume Forecast
Table 12: Europe Beta-Thalassemia Intermedia/Major Patient Volume Forecast (2016-2021)
3.2.3 Europe Beta-Thalassemia Intermedia/Major Patient Volume by Category
Table 13: Europe Beta-Thalassemia Intermedia/Major Patient Volume by Category (2016)
3.2.4 Europe Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast
Table 14: Europe Beta-Thalassemia Intermedia/Major TD Patient Volume Forecast (2016-2021)
3.2.5 Europe Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast
Table 15: Europe Beta-Thalassemia Intermedia/Major NTD Patient Volume Forecast (2016-2021)
3.2.6 Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia
Table 16: Europe Luspatercept Drug Revenue Forecast for Beta-Thalassemia (2020-2025)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Mounting Prevalence of Thalassemia
4.1.2 Increasing Pharmaceutical R&D Spending
Table 17: Global Pharmaceutical R&D Spending (2013-2016)
4.1.3 Increasing Spending on Stem Cell Research
Table 18: NIH Spending on Stem Cell Research (2013-2016)
4.1.4 Rising Healthcare Expenditure
Table 19: Global Healthcare Expenditure per Capita (2012-2016)
4.1.5 Rising Asian Population
Table 20: East Asia-Pacific Population (2012-2016)
4.2 Key Trends & Developments
4.2.1 Progressing Drugs under Pipeline
Table 21: Drugs under Development for Thalassemia (2016)
4.2.2 Rising Scope for Gene Therapy
4.2.3 Increasing Awareness towards Thalassemia
4.3 Key Challenges
4.3.1 Regulatory Challenges
4.3.2 Other Associated Risks
4.3.3 Highly Expensive Treatment
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison of Key Players
Table 22: Global Thalassemia Key Players - Revenue Comparison (2016)
5.1.2 Market Cap Comparison of Key Players
Table 23: Global Thalassemia Key Players - Market Cap Comparison (2016)
6. Company Profiles
6.1 GlaxoSmithKline Plc.
6.1.1 Business Overview
Table 24: GlaxoSmithKline Plc. Revenue by Segment (2016)
6.1.2 Financial Overview
Table 25: GlaxoSmithKline Plc. Revenue (2012-2016)
6.1.3 Business Strategies
Table 26: GlaxoSmithKline Plc. R&D Expenditure (2014-2016)
6.2 Celgene
6.2.1 Business Overview
Table 27: Celgene Revenue by Region (2016)
6.2.2 Financial Overview
Table 28: Celgene Total Revenue and Net Income (2012-2016)
6.2.3 Business Strategies
Table 29: Celgene R&D Expenditure (2014-2016)
6.3 Bluebird Bio
6.3.1 Business Overview
Table 30: Bluebird Bio’s Product Pipeline
6.3.2 Financial Overview
Table 31: Bluebird Bio Revenue and Net Loss (2012-2016)
6.3.3 Business Strategies
Table 32: Bluebird Bio R&D Expenditure (2014-2016)
6.4 Bellicum Pharmaceuticals
6.4.1 Business Overview
6.4.2 Financial Overview
Table 33: Bellicum Pharmaceuticals Revenue and Net Loss (2012-2016)
6.4.3 Business Strategies
Table 34: Bellicum Pharmaceuticals R&D Expenditure (2014-2016)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report